• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三线免疫治疗后IV期胃癌的转化手术：一例病例报告

Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report.

作者信息

Evdokimova Sevindzh F, Kornietskaya Anna L, Bolotina Larisa V, Kolobayev Iliya V, Fedenko Alexander A, Kaprin Andrey D

机构信息

P. Hertsen Moscow Oncology Research Institute - Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Moscow, Russia.

Peoples' Friendship University of Russia, Moscow, Russia.

出版信息

Front Oncol. 2024 Dec 6;14:1494669. doi: 10.3389/fonc.2024.1494669. eCollection 2024.

DOI:10.3389/fonc.2024.1494669
PMID:39711962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11659121/
Abstract

The 5-year overall survival rate for stage IV gastric cancer is lower than 10%, despite the development of systemic therapy. Conversion surgery has shown to improve survival outcomes in patients with durable clinical response on chemotherapy. We report a clinical case of a patient, who underwent conversion surgery after pembrolizumab in the third-line setting for stage IV gastric cancer. The patient did not have recurrence for 22 months after conversion surgery.

摘要

尽管有了全身治疗的进展，但IV期胃癌的5年总生存率仍低于10%。转化手术已被证明可改善对化疗有持久临床反应的患者的生存结果。我们报告了一例IV期胃癌患者的临床病例，该患者在三线治疗中接受帕博利珠单抗治疗后接受了转化手术。转化手术后该患者22个月未复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df5/11659121/a7c0618df737/fonc-14-1494669-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df5/11659121/01c0316ad86a/fonc-14-1494669-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df5/11659121/b30217df80fc/fonc-14-1494669-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df5/11659121/a7c0618df737/fonc-14-1494669-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df5/11659121/01c0316ad86a/fonc-14-1494669-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df5/11659121/b30217df80fc/fonc-14-1494669-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8df5/11659121/a7c0618df737/fonc-14-1494669-g003.jpg

相似文献

1
Conversion surgery for stage IV gastric cancer after third-line immunotherapy: a case report.三线免疫治疗后IV期胃癌的转化手术：一例病例报告
Front Oncol. 2024 Dec 6;14:1494669. doi: 10.3389/fonc.2024.1494669. eCollection 2024.
2
Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.纳武利尤单抗治疗完全病理缓解的 IV 期胃癌转化手术：病例报告。
World J Surg Oncol. 2020 Jul 21;18(1):179. doi: 10.1186/s12957-020-01954-0.
3
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.评估帕博利珠单抗治疗微卫星不稳定高或胃食管结合部癌患者的疗效：KEYNOTE-059、KEYNOTE-061 和 KEYNOTE-062 临床试验结果。
JAMA Oncol. 2021 Jun 1;7(6):895-902. doi: 10.1001/jamaoncol.2021.0275.
4
Meta-Analysis of the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced Gastric Cancer and Gastroesophageal Junction Cancer.帕博利珠单抗治疗晚期胃癌和胃食管交界癌的疗效与安全性的Meta分析
Chemotherapy. 2025;70(1):37-52. doi: 10.1159/000540071. Epub 2024 Jul 17.
5
Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy.病例报告：HER-2扩增阳性的局部晚期胃食管交界癌患者，在新辅助治疗中，在化疗加曲妥珠单抗的基础上加用帕博利珠单抗后实现了病理完全缓解。
Front Immunol. 2025 Feb 12;16:1555074. doi: 10.3389/fimmu.2025.1555074. eCollection 2025.
6
[Progress in conversion therapy for stage IV gastric cancer].[IV期胃癌转化治疗的进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):107-111. doi: 10.3760/cma.j.cn.441530-20201215-00661.
7
Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy.帕博利珠单抗治疗复发的局部晚期或转移性胃癌或胃食管交界癌患者：基于证据的治疗地位综述
Onco Targets Ther. 2018 Oct 4;11:6525-6537. doi: 10.2147/OTT.S152513. eCollection 2018.
8
[Clinical significance and efficacy of conversion surgery for patients with stage IV gastric cancer].[IV期胃癌患者转化手术的临床意义及疗效]
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Oct 25;21(10):1087-1092.
9
Conversion Surgery for Stage IV Gastric Cancer.IV期胃癌的转化手术
Front Oncol. 2019 Nov 7;9:1158. doi: 10.3389/fonc.2019.01158. eCollection 2019.
10
Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy.HER2阳性IV期胃癌转化手术的预后获益；11例接受曲妥珠单抗化疗患者的病例系列研究
Surg Case Rep. 2020 Sep 24;6(1):219. doi: 10.1186/s40792-020-00984-w.

本文引用的文献

1
The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy.接受全身化疗的IV期胃癌患者行转化手术的临床意义
Biomedicines. 2023 Nov 20;11(11):3097. doi: 10.3390/biomedicines11113097.
2
GPR176 Is a Biomarker for Predicting Prognosis and Immune Infiltration in Stomach Adenocarcinoma.GPR176 是预测胃腺癌预后和免疫浸润的生物标志物。
Mediators Inflamm. 2023 Apr 19;2023:7123568. doi: 10.1155/2023/7123568. eCollection 2023.
3
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
4
Conversion surgery for stage IV gastric cancer: a multicenter retrospective study.IV 期胃癌转化手术：一项多中心回顾性研究。
BMC Surg. 2022 Dec 14;22(1):428. doi: 10.1186/s12893-022-01874-8.
5
Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report.雷莫西尤单抗和紫杉醇二线化疗后成功进行的伴有肝转移的IV期胃癌转化手术：一例报告
Surg Case Rep. 2022 Apr 1;8(1):58. doi: 10.1186/s40792-022-01412-x.
6
Survival outcomes of management in metastatic gastric adenocarcinoma patients.转移性胃腺癌患者管理的生存结果。
Sci Rep. 2021 Nov 30;11(1):23142. doi: 10.1038/s41598-021-02391-z.
7
Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.纳武利尤单抗治疗完全病理缓解的 IV 期胃癌转化手术：病例报告。
World J Surg Oncol. 2020 Jul 21;18(1):179. doi: 10.1186/s12957-020-01954-0.
8
Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.晚期/转移性胃癌或胃食管结合部癌患者在不同治疗线的真实世界治疗模式和临床结局。
Clin Colorectal Cancer. 2020 Mar;19(1):32-38.e3. doi: 10.1016/j.clcc.2019.09.001. Epub 2019 Sep 24.
9
Long-term Results of Conversion Therapy for Initially Unresectable Gastric Cancer: Analysis of 122 Patients at the National Cancer Center in China.初始不可切除胃癌转化治疗的长期结果：中国国家癌症中心122例患者分析
J Cancer. 2019 Oct 15;10(24):5975-5985. doi: 10.7150/jca.35527. eCollection 2019.
10
Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review.晚期/转移性胃癌的三线全身治疗：综述
Ther Adv Med Oncol. 2019 Jun 29;11:1758835919859990. doi: 10.1177/1758835919859990. eCollection 2019.